Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $5.84 million. The enterprise value is -$22,148.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 13.32 million shares outstanding. The number of shares has increased by 87.67% in one year.
| Current Share Class | 13.32M |
| Shares Outstanding | 13.32M |
| Shares Change (YoY) | +87.67% |
| Shares Change (QoQ) | +48.59% |
| Owned by Insiders (%) | 10.37% |
| Owned by Institutions (%) | 4.49% |
| Float | 10.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.49 |
| Forward PS | n/a |
| PB Ratio | 0.92 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.70
| Current Ratio | 8.70 |
| Quick Ratio | 8.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,088.94 |
Financial Efficiency
Return on equity (ROE) is -86.11% and return on invested capital (ROIC) is -56.27%.
| Return on Equity (ROE) | -86.11% |
| Return on Assets (ROA) | -44.37% |
| Return on Invested Capital (ROIC) | -56.27% |
| Return on Capital Employed (ROCE) | -93.50% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.69M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.72% in the last 52 weeks. The beta is 0.64, so Silo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -54.72% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 0.75 |
| Relative Strength Index (RSI) | 42.22 |
| Average Volume (20 Days) | 138,676 |
Short Selling Information
The latest short interest is 67,438, so 0.51% of the outstanding shares have been sold short.
| Short Interest | 67,438 |
| Short Previous Month | 134,766 |
| Short % of Shares Out | 0.51% |
| Short % of Float | 0.66% |
| Short Ratio (days to cover) | 0.98 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$5.08 million in losses. Loss per share was -$0.82.
| Revenue | 72,102 |
| Gross Profit | 47,036 |
| Operating Income | -5.31M |
| Pretax Income | -5.08M |
| Net Income | -5.08M |
| EBITDA | -5.30M |
| EBIT | -5.31M |
| Loss Per Share | -$0.82 |
Full Income StatementBalance Sheet
The company has $5.87 million in cash and n/a in debt, giving a net cash position of $5.87 million or $0.44 per share.
| Cash & Cash Equivalents | 5.87M |
| Total Debt | n/a |
| Net Cash | 5.87M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 5.01M |
| Book Value Per Share | 0.48 |
| Working Capital | 5.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.80M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 65.24% |
| Operating Margin | -7,361.09% |
| Pretax Margin | -7,041.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |